As one of the first CSC markers, EpCAM has been evaluated as a therapeutic biomarker (compare Tables 1–5). Targeting EpCAM with different antibody formats has been performed in colorectal as well as breast cancers (347). In colorectal cancers, a therapeutic approach targeting EpCAM+ cells with aptamers has been performed in pre-clinical conditions (345, 346).